These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8599081)

  • 1. Evolving catalysts in real time.
    Davis MM
    Science; 1996 Feb; 271(5252):1078-9. PubMed ID: 8599081
    [No Abstract]   [Full Text] [Related]  

  • 2. The immunological evolution of catalysis.
    Patten PA; Gray NS; Yang PL; Marks CB; Wedemayer GJ; Boniface JJ; Stevens RC; Schultz PG
    Science; 1996 Feb; 271(5252):1086-91. PubMed ID: 8599084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolutionary chemistry: getting there from here.
    Joyce GF
    Science; 1997 Jun; 276(5319):1658-9. PubMed ID: 9206829
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural insights into the evolution of an antibody combining site.
    Wedemayer GJ; Patten PA; Wang LH; Schultz PG; Stevens RC
    Science; 1997 Jun; 276(5319):1665-9. PubMed ID: 9180069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic antibodies: evolution of protein function in real time.
    Lerner RA; Janda KD
    EXS; 1995; 73():121-38. PubMed ID: 7579971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological origins of binding and catalysis in a Diels-Alderase antibody.
    Romesberg FE; Spiller B; Schultz PG; Stevens RC
    Science; 1998 Mar; 279(5358):1929-33. PubMed ID: 9506942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of the affinity maturation of antibody 48G7.
    Yang PL; Schultz PG
    J Mol Biol; 1999 Dec; 294(5):1191-201. PubMed ID: 10600377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From molecular diversity to catalysis: lessons from the immune system.
    Schultz PG; Lerner RA
    Science; 1995 Sep; 269(5232):1835-42. PubMed ID: 7569920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.
    Takahashi-Ando N; Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2004 Nov; 294(1-2):1-14. PubMed ID: 15604011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune recognition, antigen design, and catalytic antibody production.
    Tramontano A
    Appl Biochem Biotechnol; 1994; 47(2-3):257-73; discussion 273-5. PubMed ID: 7944342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-directed mutagenesis of proteolytic antibody light chain.
    Gao QS; Sun M; Rees AR; Paul S
    J Mol Biol; 1995 Nov; 253(5):658-64. PubMed ID: 7473741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive immunization.
    Wirsching P; Ashley JA; Lo CH; Janda KD; Lerner RA
    Science; 1995 Dec; 270(5243):1775-82. PubMed ID: 8525366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and fluorescence studies of affinity maturation in related antibodies.
    Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
    Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative analysis of the immunological evolution of antibody 28B4.
    Yin J; Mundorff EC; Yang PL; Wendt KU; Hanway D; Stevens RC; Schultz PG
    Biochemistry; 2001 Sep; 40(36):10764-73. PubMed ID: 11535051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Completing the circle.
    Schultz PG; Lerner RA
    Nature; 2002 Aug; 418(6897):485. PubMed ID: 12152057
    [No Abstract]   [Full Text] [Related]  

  • 16. Exploiting antibodies as catalysts: potential therapeutic applications.
    Tellier C
    Transfus Clin Biol; 2002 Jan; 9(1):1-8. PubMed ID: 11889895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding and catalysis: a thermodynamic study on a catalytic antibody system.
    Wade H; Scanlan TS
    Chembiochem; 2003 Jun; 4(6):537-40. PubMed ID: 12794866
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody catalysis via strategic use of haptenic charge.
    Kikuchi K; Hilvert D
    Acta Chem Scand (Cph); 1996 Apr; 50(4):333-6. PubMed ID: 8639376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interplay between binding energy and catalysis in the evolution of a catalytic antibody.
    Ulrich HD; Mundorff E; Santarsiero BD; Driggers EM; Stevens RC; Schultz PG
    Nature; 1997 Sep; 389(6648):271-5. PubMed ID: 9305839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.